Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin

• Published in: BMC cancer 2008-01, Vol.8 (1), p.28-28, Article 28
• Main Authors: Ben Hamida, Azza, Labidi, Intidhar S, Mrad, Karima, Charafe-Jauffret, Emmanuelle, Ben Arab, Saïda, Esterni, Benjamin, Xerri, Luc, Viens, Patrice, Bertucci, François, Birnbaum, Daniel, Jacquemier, Jocelyne
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Biological markers; Biomarkers, Tumor - analysis; Breast cancer; Breast Neoplasms - chemistry; Breast Neoplasms - classification; Breast Neoplasms - complications; Breast Neoplasms - pathology; Cadherins - analysis; Cancer; Carcinoma, Ductal, Breast - chemistry; Carcinoma, Ductal, Breast - classification; Carcinoma, Ductal, Breast - complications; Carcinoma, Ductal, Breast - secondary; Female; Genetic aspects; Health aspects; Humans; Immunohistochemistry; Inflammation - complications; Life Sciences; Membrane proteins; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Prognosis; Receptor, ErbB-2 - metabolism; Receptors, Estrogen - metabolism; Risk factors
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/1471-2407-8-28

Inflammatory breast cancer (IBC) is a distinct and aggressive form of locally-advanced breast cancer with high metastatic potential. In Tunisia, IBC is associated with a high death rate. Among the major molecular subtypes, basal breast carcinomas are poorly differentiated, have metastatic potential and poor prognosis, but respond relatively well to chemotherapy. The aim of this study was to determine the distribution of molecular subtypes in IBC and identify factors that may explain the poor prognosis of IBC. To determine breast cancer subtypes we studied by immunohistochemistry the expression of 12 proteins in a series of 91 Tunisian IBC and 541 non-IBC deposited in tissue microarrays. We considered infiltrating ductal cases only. We found 33.8% of basal cases in IBC vs 15.9% in non-IBC (p < 0.001), 33.3% of ERBB2-overexpressing cases in IBC vs 14.5% in non-IBC (p < 0.001), and 29.3% of luminal cases in IBC vs 59.9% in non-IBC (p < 0.001). The most differentially-expressed protein between IBCs and non-IBCs was P-cadherin. P-cadherin expression was found in 75.9% of all IBC vs 48.2% of all non-IBC (p < 0.001), 95% of IBC vs 69% of non-IBC (p = 0.02) in basal cases, and 82% of IBC vs 43% of non-IBC (p < 0.001) in luminal cases. Logistic regression determined that the most discriminating markers between IBCs and non-IBCs were P-cadherin (OR = 4.9, p = 0.0019) MIB1 (OR = 3.6, p = 0.001), CK14 (OR = 2.7, p = 0.02), and ERBB2 (OR = 2.3, p = 0.06). Tunisian IBCs are characterized by frequent basal and ERBB2 phenotypes. Surprisingly, luminal IBC also express the basal marker P-cadherin. This profile suggests a specificity that needs further investigation.